{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:49:00Z","timestamp":1790092140422,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.111008","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:41:06Z","timestamp":1771735266000},"page":"111008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of the tumor microenvironment in penile carcinoma and emerging therapeutic concepts: A review"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0633-1728","authenticated-orcid":false,"given":"August","family":"Fiegl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Mink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.111008_bib0001","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ad.2011.08.008","article-title":"\u201cPenile squamous cell carcinoma.\u201d","volume":"103","author":"Ferr\u00e1ndiz-Pulido","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.urolonc.2026.111008_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.111008_bib0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41585-021-00557-y","article-title":"A global approach to improving penile cancer care","volume":"19","author":"Bandini","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0004","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ijc.31194","article-title":"\"Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956\u20132015.\"","volume":"142","author":"Hansen","year":"2018","journal-title":"Int J Ca"},{"key":"10.1016\/j.urolonc.2026.111008_bib0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2007.14.1713","article-title":"Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States","volume":"26","author":"Chaturvedi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0006","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2008.01.041","article-title":"New aspects of vulvar cancer: changes in localization and age of onset","volume":"109","author":"Hampl","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0007","unstructured":"\"Seer*explorer: An interactive website for seer cancer statistics. Surveillance research program, National Cancer Institute; 2023 apr 19. [updated: 2023 nov 16; cited 2024 feb 18]. Available from: Https:\/\/seer.Cancer.Gov\/statistics-network\/explo.\""},{"key":"10.1016\/j.urolonc.2026.111008_bib0008","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5173\/ceju.2014.02.art2","article-title":"Metastatic penile carcinoma: an update on the current diagnosis and treatment options","volume":"67","author":"Barski","year":"2014","journal-title":"Central Eur J Urol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0009","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/1055-9965.EPI-18-0322","article-title":"Prognostic significance of HPV and p16 status in men diagnosed with penile cancer: a systematic review and meta-analysis","volume":"27","author":"Sand","year":"2018","journal-title":"Ca Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2026.111008_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2013.07.088","article-title":"Contemporary management of regional nodes in penile cancer-improvement of survival?","volume":"191","author":"Djajadiningrat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0011","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00345-017-2167-5","article-title":"Prognostic factors in patients with penile cancer after surgical management","volume":"36","author":"Wen","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0012","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1590\/S1677-5538.IBJU.2013.04.12","article-title":"Human papilloma virus: prevalence, distribution and predictive value to lymphatic metastasis in penile carcinoma","volume":"39","author":"Fonseca","year":"2013","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0013","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.juro.2010.03.145","article-title":"Development and evaluation of a nomogram to predict inguinal lymph node metastasis in patients with penile cancer and clinically negative lymph nodes","volume":"184","author":"Zhu","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.urology.2016.06.033","article-title":"Predictors of nodal upstaging in clinical node negative patients with penile carcinoma: a national cancer database analysis","volume":"96","author":"Winters","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.111008_bib0015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2024.03.038","article-title":"Single-cell atlas of penile cancer reveals tp53 mutations as a driver of an aggressive phenotype, irrespective of human papillomavirus status, and provides clues for treatment personalization","volume":"86","author":"Elst","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0016","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.pathol.2023.03.010","article-title":"Immune cell infiltration, tumour budding, and the p53 expression pattern are important predictors in penile squamous cell carcinoma: a retrospective study of 152 cases","volume":"55","author":"Hrudka","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.urolonc.2026.111008_bib0017","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 world health organization classification of tumors of the urinary system and male genital organs-part b: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0018","article-title":"The prognostic role of HPV or p16ink4a status in penile squamous cell carcinoma: a meta-analysis","volume":"23","author":"Mustasam","year":"2025","journal-title":"J Natl Comprehens Ca Netw"},{"key":"10.1016\/j.urolonc.2026.111008_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00428-019-02566-0","article-title":"Challenging the prognostic impact of the new WHO and TNM classifications with special emphasis on HPV status in penile carcinoma","volume":"475","author":"H\u00f6lters","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.urolonc.2026.111008_bib0020","doi-asserted-by":"crossref","first-page":"605.e17","DOI":"10.1016\/j.urolonc.2017.06.001","article-title":"Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study","volume":"35","author":"Tang","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0021","doi-asserted-by":"crossref","first-page":"e2348002","DOI":"10.1001\/jamanetworkopen.2023.48002","article-title":"Genomic profiles and clinical outcomes of penile squamous cell carcinoma with elevated tumor mutational burden","volume":"6","author":"Necchi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.111008_bib0022","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000495251","article-title":"No evidence of microsatellite instability and loss of mismatch-repair-protein expression in squamous cell carcinoma of the penis","volume":"86","author":"Stoehr","year":"2019","journal-title":"Pathobiology"},{"key":"10.1016\/j.urolonc.2026.111008_bib0023","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.3390\/curroncol31100427","article-title":"Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in penile squamous cell carcinoma: no evidence for a role in carcinogenesis","volume":"31","author":"Fiegl","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0024","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/01.ju.0000154565.37397.4d","article-title":"Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases","volume":"173","author":"Kroon","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0025","first-page":"374","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Ca Cell"},{"key":"10.1016\/j.urolonc.2026.111008_bib0026","article-title":"A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-pd-1 therapy response","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.urolonc.2026.111008_bib0027","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of fap(+) fibroblasts and spp1(+) macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2026.111008_bib0028","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","article-title":"Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression","volume":"23","author":"Chen","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0029","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/s12276-022-00896-9","article-title":"Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics","volume":"54","author":"Zhu","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.urolonc.2026.111008_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70855-z","article-title":"The impact of the tumor microenvironment on the survival of penile cancer patients","volume":"14","author":"Lohse","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.111008_bib0031","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3389\/fimmu.2018.01253","article-title":"The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma","volume":"9","author":"Ottenhof","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0032","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s13277-014-2864-2","article-title":"Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: fox-p3 expression is an independent predictor of recurrence","volume":"36","author":"Vassallo","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0033","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-024-04013-1","article-title":"Tumor-infiltrating plasma cells are a prognostic factor in penile squamous cell carcinoma","author":"Stenzel","year":"2025","journal-title":"Virchows Arch"},{"key":"10.1016\/j.urolonc.2026.111008_bib0034","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/1535-7163.MCT-20-0173","article-title":"The hpv and p63 status in penile cancer are linked with the infiltration and therapeutic availability of neutrophils","volume":"20","author":"Bernhard","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2026.111008_bib0035","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/jnci\/djad155","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the global society of rare genitourinary tumors","volume":"115","author":"El Zarif","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2026.111008_bib0036","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1200\/JCO.22.02894","article-title":"Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (the Pericles study): a phase II trial","volume":"41","author":"de Vries","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0037","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ccell.2025.03.023","article-title":"Neoadjuvant toripalimab plus nimotuzumab combined with Taxol-based chemotherapy in locally advanced penile squamous cell carcinoma","volume":"43","author":"An","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.111008_bib0038","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1200\/JCO.2024.42.16_suppl.5009","article-title":"A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: Hercules (lacog 0218) trial","volume":"42","author":"Maluf","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.urolonc.2026.111008_bib0039","article-title":"EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma","volume":"43","author":"Bahl","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1200\/JCO.2025.43.5_suppl.9","article-title":"Epic-b: phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma","volume":"43","author":"Challapalli","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0041","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.111008_bib0042","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0043","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5108","article-title":"A phase II trial of enfortumab vedotin for locally advanced and metastatic squamous cell carcinoma of the penis","volume":"42","author":"Pagliaro","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216109","article-title":"Metastatic penile squamous cell carcinoma responsive to enfortumab vedotin","volume":"24","author":"Fahey","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2026.111008_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100781","article-title":"Evaluation of nectin-4 and trop-2: implications for patient outcomes and therapy in penile cancer","author":"Mink","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0046","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 16","key":"10.1016\/j.urolonc.2026.111008_bib0047","article-title":"A phase II trial of enfortumab vedotin for locally advanced and metastatic squamous cell carcinoma of the penis","volume":"42","author":"Pagliaro","year":"2024","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113360","article-title":"The role of her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy","volume":"194","author":"Tan","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2026.111008_bib0049","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: tropics-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0051","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4627","volume":"42","author":"Kydd","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0052","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.urolonc.2026.111008_bib0053","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0054","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (immu-132), an anti-trop-2\/sn-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.urolonc.2026.111008_bib0055","doi-asserted-by":"crossref","first-page":"31411","DOI":"10.18632\/oncotarget.25830","article-title":"Topoisomerase i inhibitor, irinotecan, depletes regulatory t cells and up-regulates mhc class i and pd-l1 expression, resulting in a supra-additive antitumor effect when combined with anti-pd-l1 antibodies","volume":"9","author":"Iwai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2026.111008_bib0056","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (sg) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated pd-l1\u2013positive advanced triple-negative breast cancer (tnbc): primary results from the randomized phase 3 ascent-04\/keynote-d19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0057","doi-asserted-by":"crossref","first-page":"S680","DOI":"10.1016\/j.annonc.2024.08.1058","article-title":"999mo hare-40: a phase I\/II trial of therapeutic hpv vaccine (bnt113) in patients with hpv16 driven carcinoma","volume":"35","author":"Ottensmeier","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0058","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","article-title":"Synergistic efficacy of simultaneous anti-tgf-\u03b2\/vegf bispecific antibody and pd-1 blockade in cancer therapy","volume":"16","author":"Niu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0059","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to pd1\/pdl1 checkpoint inhibition","volume":"52","author":"O'Donnell","year":"2017","journal-title":"Ca Treatment Rev"},{"key":"10.1016\/j.urolonc.2026.111008_bib0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8670","article-title":"A global Phase II\/3, randomized, open-label trial of bnt327\/pm8002 in combination with chemotherapy (chemo) in first-line (1l) non-small cell lung cancer (nsclc)","volume":"43","author":"Peters","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0061","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for pd-l1-positive non-small cell lung cancer (harmoni-2): a randomised, double-blind, phase 3 study in china","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.111008_bib0062","article-title":"A phase II trial to evaluate the safety and efficacy of ssgj-707, a bispecific antibody targeting pd-1 and vegf, as a monotherapy in patients with advanced nsclc","volume":"43","author":"Wu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111008_bib0063","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8511","article-title":"First report of efficacy and safety results from a Phase II trial evaluating bnt327\/pm8002 plus chemotherapy (chemo) as first-line treatment (1l) in unresectable malignant mesothelioma","volume":"43","author":"Cheng","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:40:41Z","timestamp":1776577241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1078143926000190"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the tumor microenvironment in penile carcinoma and emerging therapeutic concepts: A review","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111008"}}